Protected antibody-drug and aptamer-drug conjugates

#This is a Continuation in Part (CIP), and Nonprovisional U.S. Patent Application of Provisional U.S. Patent Application No. 62/786,340, filed Dec. 29, 2018, (herein called App. 62/786,340), the entire contents, including suitable methods and examples, and references therein which are hereby incorporated by reference as if fully set forth herein. All patent applications, patents, and publications, including supplementary materials, and additional references therein, that are cited herein, are hereby incorporated herein by reference in their entireties, except for any conflicting definitions, subject matter disclaimers or disavowals, and except to the extent that the incorporated material is inconsistent or in conflict with the express disclosures herein, in which case the language in this disclosure controls.

#For this invention, certain useful compositions and synthesis methods, and all categories of active agents, ligands, all intercalators of nucleic acids and peptides, any antibodies, any nucleic acids, including carrier nucleic acid compositions, peptide nucleic acids (PNA) and derivatized nucleic acids, splicing RNA (spRNA), DNAzymes, any polymers, targeting moieties, target substances including cancer cells, disease microorganisms and biomarkers, coupling agents and functional groups, are all suitably modified as needed. All compositions that would be useful for this invention after suitable modification, defined herein, including crRNAs, sgRNAs, any CRISPR proteins and compositions, any zinc finger proteins and compositions, any TALEN proteins and compositions and any suitable derivatives thereof.

#The instant application contains Sequence ID numbers, and a Sequence Listing which has been submitted in computer readable form (CRF), in ASCII format, file name: “AbDrugSeq16_729_297_Feb24_ST25.txt”, and is hereby incorporated by reference in its entirety for all purposes.

#FIG. 1 is: Example Diagram 1. CLL COmposition With a Valine-Citrulline-Glycine Cleavabie Linkage Sequence With Optional Moieties.

#FIG. 2 is: Example Diagram II-A. Branched Cleavabie Linkage.

#FIG. 3 is: Example Diagram V-A. Folded Drug Carrier Aptamer Composition and Structural LOOP.

#This invention discloses and claims new compositions that are in the field of nanomedicine compositions and drug delivery compositions. This invention comprises drugs or “active agents”, defined herein, coupled with specific molecular, or nano-sized substances, compositions, or drug carrier, molecular compositions (“carriers”), not meant to include solvents, solubilizers, excipients, etc., used in certain formulations. This invention includes antibodies and aptamers and molecular coatings for medical devices, for delivering and releasing said active agents (i.e. drugs), to the desired target cells, tissues or organs for pharmaceutical or agricultural use. This invention is also applicable to in vitro diagnostic testing and research use. The compositions of this invention include carrier substances defined herein with active agents, defined herein coupled through covalent, cleavable linkages or by noncovalent coupling between said active agent and said carrier defined herein. The compositions can also contain covalently coupled said active agents that also function as ligands with noncovalent coupling with a ligand binding domain defined herein.

#Said compositions of this invention can include at least one targeting moiety or biorecognition molecule, defined herein, capable of binding to its intended target substance. The compositions can include various carrier substances to which active agents are coupled that can include any suitable aptamers and/or proteins including antibodies, polypeptides, nucleic acids, polysaccharides, synthetic polymers, micelles, nanoparticles and other substances known in the art for carrying and releasing the active agents into the body for therapeutic effect. The invention also discloses methods for preparing and using said compositions.

#Various substances, including antibodies are coupled with active agents and used as drug carriers in various therapies such as treatment for cancer and other diseases. In the prior art, said active agents are released unintentionally from a variety of carriers primarily through chemical means that includes catalytic or enzymatic degradation or cleavage of linkages between the active agent and the carrier.